PBAC's latest decision on Fosnetupitant/palonosetron: Recommended with restriction (2023). Considered for Prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly or moderately emetogenic cancer chemotherapy.
PBAC outcome
Recommended with restriction
Authority Required
ICER (AUD/QALY)
Cost-min
cost-minimisation analysis
Submissions
1
first 2023
Submissions
1
2023 → 2023
Eligible population
Adult patients receiving highly or moderately emetogenic chemotherapy for cancer (including breast cancer with AC chemotherapy, carboplatin/oxaliplatin regimens, and other specified emetogenic agents) who require prophylaxis of chemotherapy-induced nausea and vomiting.
Therapy area
Gastroenterology
Line of therapy
Not applicable
Evidence base
RCT
Primary endpoint
ORR
Key trials
CONSOLE, CONSOLE-BC
Comparator
fosaprepitant 150 mg (Emend IV) plus palonosetron
Economic model
Cost-minimisation
ICER note
Cost-minimisation analysis; no ICER calculated by design.